ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma

We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krakstad, Camilla, Tangen, Ingvild L., Hoivik, Erling A., Halle, Mari K., Berg, Anna, Werner, Henrica M., Ræder, Maria B., Kusonmano, Kanthida, Zou, June X., Øyan, Anne M., Stefansson, Ingunn, Trovik, Jone, Kalland, Karl-Henning, Chen, Hong-Wu, Salvesen, Helga B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://www.ncbi.nlm.nih.gov/pubmed/26308378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://www.ncbi.nlm.nih.gov/pubmed/26308378

Ejemplares similares